Previous Article | Next Article 
Journal of Virology, March 2001, p. 2938-2945, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2938-2945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Internal Ribosome Entry Site Regulates Translation
of Kaposi's Sarcoma-Associated Herpesvirus FLICE Inhibitory
Protein
Walter
Low,1
Mark
Harries,1
Hongtao
Ye,2
Ming-Qing
Du,2
Chris
Boshoff,3 and
Mary
Collins1,*
Windeyer Institute of Medical Sciences,
University College London,1 and
Department of Histopathology2 and
Wolfson Institute for Biomedical
Research,3 Royal Free and University College
Medical School, London, United Kingdom
Received 26 October 2000/Accepted 15 December 2000
 |
ABSTRACT |
The gammaherpesvirus Kaposi's sarcoma-associated herpesvirus
(KSHV) (or human herpesvirus 8) is associated with the endothelial tumor Kaposi's sarcoma (KS) and lymphoproliferative disorders in
immunocompromised individuals. Only a small number of viral proteins
are expressed in B cells latently infected with KSHV; here we
characterize the mechanism of expression of one of these, the viral
FLICE inhibitory protein v-FLIP (K13, ORF71). The v-FLIP coding region
is present in a bicistronic message, following the v-cyclin coding
region. Using both in vitro translation and cell transfection assays,
we have identified an internal ribosome entry site (IRES) preceding the
v-FLIP start codon and overlapping the v-cyclin (ORF 72) coding region,
which allows v-FLIP translation. Using an antibody against v-FLIP we
have detected expression of the endogenous protein in latently infected
KSHV-positive primary effusion lymphoma (PEL) cell lines. Induction of
apoptosis by serum withdrawal from PEL cells results in a relative
increase in v-FLIP synthesis, as previously described for some cellular proteins translated from IRES.
 |
INTRODUCTION |
In 1994 Kaposi's sarcoma
(KS)-associated herpesvirus (KSHV) was first identified in an AIDS-KS
patient (15). KSHV DNA is present in all epidemiological
types of KS and can be detected in all fresh biopsies and most
paraffin-embedded lesions (9, 33a). KSHV sequences are also present in
hematopoietic tumors primary effusion lymphoma (PEL) and a subtype of
multicentric Castleman's disease (MCD) (13, 20, 59). PEL
represents the clonal expansion of virally infected B lymphocytes
(36). MCD is a polyclonal proliferation of mantle zone B
cells, with only a few cells within the lesion infected by KSHV
(20, 21, 36, 59). Sequencing the KSHV genome revealed that
the virus has acquired a large number of cellular genes which might
affect cell proliferation, differentiation, or death (8, 45, 46,
54). Of these, the v-cyclin (ORF 72), the viral FLICE inhibitory
protein (v-FLIP, K13, ORF71), v-interleukin-6 (v-IL-6), and one of the
viral interferon response factors are transcribed in some latently
infected PEL cell lines (45, 60), and the v-FLIP and
v-cyclin are transcribed in latently infected KS spindle cells
(60).
A single transcript containing the sequences of the viral latent
nuclear antigen (LNA-1, ORF 73), the v-cyclin, and v-FLIP has been
detected by in site reverse transcriptase PCR in latently infected KS
spindle cells and B cells, as has a spliced derivative encoding
v-cyclin and v-FLIP (17, 18, 37, 53, 56, 61, 65). The
longer form is thought to express LNA-1, while v-cyclin and v-FLIP are
believed to be coexpressed from the spliced bicistronic transcript.
Northern hybridization analysis of RNA from PEL cell lines BC-1
(56) and BCP-1 (65) with a v-FLIP probe
failed to detect a monocistronic v-FLIP transcript.
Expression of v-cyclin protein has been detected in PEL cell lines and
primary isolates (12, 50). v-Cyclin is a D-type cyclin
which binds to cellular cyclin-dependent kinase 6 (CDK6) to form an
active kinase (15, 29, 42). LNA-1 maintains the viral
episome and tethers KSHV DNA to chromatin during mitosis (3) and may contribute to cell transformation by
inhibiting p53 and retinoblastoma protein function (25,
52). Cellular FLIPs and FLIPs encoded by other viruses block
Fas-mediated apoptosis (34, 66), and expression of KSHV
v-FLIP has been shown to enhance growth of a mouse tumor by blocking
cytotoxic-T-cell lysis (19). v-FLIP has also been shown to
activate NF-
B signaling (16).
As v-cyclin and v-FLIP coding sequences are present within a single
transcript, in situ reverse transcriptase PCR results do not define
how, or indeed whether, the proteins are coexpressed in cells latently
infected with KSHV. For the majority of cellular messages the 5' mRNA
cap is essential for binding part of the translation initiation
complex. A 43S preinitiation complex then scans the RNA until it
reaches the first favorable initiation codon for translation, which is
often the first AUG. The nucleotides surrounding the initiation codon
are important; analysis of eukaryotic mRNAs has defined a consensus
sequence for the initiation of translation (40). Following
initiation, elongation occurs until a termination codon is reached.
Occasionally, the 40S ribosome can stay bound to the RNA after the
termination codon and continue scanning to the next favorable
initiation codon to translate a further message. This process, known as
reinitiation of translation, appears to be favored by a short first
message (up to 30 codons) and an optimal intercistronic distance of
about 80 nucleotides (nt) (41).
Cap-independent translation was first described for poliovirus, where a
sequence in the 5' untranslated region which could mediate internal
initiation of translation when inserted into a bicistronic plasmid was
identified (49). Such RNA regions, which can mediate
cap-independent translation, have become known as internal ribosome
entry sites (IRES) and contain conserved elements of secondary
structure which allow direct binding of a translation initiation
complex (reviewed in reference 35). IRES have now been
identified in a number of RNA viruses with positive-sense, nonsegmented
genomes (4-7, 27, 28, 67). Our aims were therefore to
determine how the second, v-FLIP, reading frame is translated and to
examine v-FLIP expression and its regulation in KSHV-infected B cells.
 |
MATERIALS AND METHODS |
IRES analysis.
The v-cyclin/v-FLIP coding sequence of 1,423 nt, including both the initiation codon for v-cyclin and the
termination codon for v-FLIP, was amplified by PCR from plasmid
IgHP/E-73cycK13. The 5' primer contained a Kozak consensus. This
fragment was subcloned into the BamHI-XhoI sites
of pcDNA 3.1(+) (Invitrogen) to give plasmid pcDNA3.1-cyclinFLIP-(wt)
with the T7 bacteriophage promoter upstream of the v-cyclin/v-FLIP
coding sequence. Mutations in the cyclin coding sequence were made by
site-directed mutagenesis to give pcDNA3.1-cyclinFLIP-(frame shift), in
which a base from the second codon for v-cyclin was deleted resulting
in a 10-codon nonsense open reading frame and
pcDNA3.1-cyclinFLIP-(truncation), in which codon 135 of v-cyclin was
mutated to a stop. The monocistronic v-FLIP coding sequence was
amplified by PCR from plasmid IgHP/E-73cycK13 with a 5' primer that
encoded an N-terminal HA epitope. The v-cyclin coding sequence was also
amplified by PCR from plasmid IgHP/E-73cycK13 with a 5' primer
containing a Kozak consensus. Both were subcloned into pcDNA 3.1(+).
pcDNA 3.1(+) was used as a vector control. The plasmids were linearized
by digestion with XhoI prior to in vitro transcription.
PCR was used to amplify fragments corresponding to the 82, 363, and 655 nt proximal to the v-FLIP AUG from plasmid IgHP/E-73cycK13. PCR
fragments were cloned into the ClaI-NcoI sites of
plasmid pBSK-p35-p40 (31) between the coding sequences for
the two subunits of IL-12 in which the NcoI site contains
the initiation codon for p40. Plasmid pBSK-E12 (31),
containing the IRES from encephalomyocarditis virus (EMCV) between the
coding sequences for the IL-12 subunits was used as a positive control
for IRES function. In each case cassette p35-IRES-p40 was excised with
BamHI and inserted into pcDNA 3.1(+). Plasmids pcDNA-p40 and
pcDNA-p35 contain the coding sequences for individual p35 and p40
subunits of IL-12 respectively. The above constructs and an empty pcDNA
3.1(+) control were linearized by digestion with NotI prior
to in vitro transcription.
Plasmids were transcribed to produce capped RNA using the
mMESSAGEmMACHINE kit (Ambion). RNA was precipitated by adding an
equal volume of isopropanol and chilling at

20°C for 20 min.
RNA
size and concentration were determined by running an aliquot
on a 1%
agarose-formaldehyde gel. The translation reaction mixture
was
assembled from 5 µl of amino acid mixture, 5 µl of 0.2 M creatine
phosphate, 5 µl of 2 M KCl-10 mM MgCl
2, 5 µl of
[
35S]methionine-cysteine mixture (Amersham Pharmacia),
and 80 µl
of rabbit reticulocyte lysate. Equal amounts of capped,
full-length
RNA were added to 10 to 20 µl of translation mixture and
incubated
at 30°C for 90 min. Then 1 µl was removed and added to 9 µl of
sodium dodecyl sulfate (SDS) sample buffer for resolution by
SDS-polyacrylamide
gel electrophoresis
(PAGE).
293T-cell transfection.
Semiconfluent 10-cm-diameter dishes
of 293T cells were transfected with 8 µg of plasmid using
Lipofectamine. After 6 h of incubation at 37°C the cells were
washed and incubated in Dulbecco's modified Eagle's medium containing
10% fetal calf serum (FCS) at 37°C for a further 48 h.
Anti-v-FLIP polyclonal antibodies were raised in rabbits against a
keyhole limpet hemocyanin-conjugated peptide corresponding to the
N-terminal region of v-FLIP (TYEVLCEVARKLGT) (Severn Biotech). The
immunization protocol was as described in reference 30. Anti-v-FLIP rat
monoclonal antibody 6/14 was raised against full-length recombinant
v-FLIP expressed in Escherichia coli. For immunodetection
the polyclonal anti-v-FLIP rabbit serum was diluted 1:250 and detected
by a goat anti-rabbit horseradish peroxidase (HRPO) antibody (1:2,000;
Harlan) and enhanced chemiluminescence (Amersham) and the purified
monoclonal anti-v-FLIP antibody was diluted 1:100 and detected by a
goat anti-rat HRPO antibody (1:2,000; Harlan). The anti-v-cyclin was a
rat monoclonal antibody (kind gift from Sybille Mittnacht, Institute of
Cancer Research, London, United Kingdom) used at a dilution of 1:100
and detected with goat anti-rat HRPO (1:2,000; Harlan). Total cellular
RNA was isolated using the RNAzol (Biogenesis) method, in accordance
with the manufacturer's instructions. For RNA blot analysis, 10 µg
of total RNA was loaded on a 1% agarose-formaldehyde gel and
transferred to a nylon HybondN+ membrane (Amersham). Prehybridization,
hybridization, and washes of the membrane were performed using the
HybondN+ protocol. The v-FLIP and p40 probes were labeled with
[
-32P]dCTP (Amersham) using a random-prime-labeling
system (Promega). IL-12 was determined using a commercial sandwich
enzyme-linked immunosorbent assay (ELISA) with antibodies which detect
the p40 subunit; each supernatant was assayed in triplicate (Cytoscreen human IL-12; BioSource International Inc.).
v-FLIP expression in KSHV-infected cells.
The
KSHV-transformed primary effusion lymphoma (PEL) cell lines BC3 and
BCP1 (10, 26), Epstein-Barr virus (EBV)-transformed B-cell
line B.45, and EBV-negative B-cell line DG75 were cultured in RPMI 1640 supplemented with 10% FCS, penicillin, and streptomycin at 37°C in
5% CO2. For immunostaining BC3 cells were fixed in 3%
paraformaldehyde for 10 min and then washed in 0.2% Triton X-100 for 5 min. Cells were stained for v-FLIP with rat monoclonal antibody 6/14
(1/30 dilution), followed by a biotinylated rabbit anti-mouse antibody
and peroxidase-conjugated avidin. The stained proteins were visualized
with diaminobenzidine tetrahydrochloride and briefly counterstained
with hematoxylin. For immunoprecipitation BC3 cells were washed twice
with serum-free RPMI 1640 and incubated for 20 to 24 h in RPMI
1640 with or without serum. Cells were then incubated for 30 min in
methionine- and cysteine-free RPMI1640 (Sigma) and then labeled for
2 h in the same medium supplemented with a mixture of
[35S]methionine-cysteine (Redivue Pro-Mix; Amersham) and,
where appropriate, with 10% FCS. After three washes in ice-cold
phosphate-buffered saline (PSB), the cell pellets were lysed for 30 min
on ice in 1 ml of radioimmunoprecipitation assay buffer
(30) supplemented with protease inhibitors. Lysates were
then centrifuged at 14,000 × g for 15 min at 4°C.
Supernatant from the equivalent of 107 cells was precleared
for 1 h with protein G-Sepharose (Sigma) for anti-LNA-1
(38) or protein A-sepharose (Sigma) for anti-v-FLIP and
then immunoprecipitated for 2 h at 4°C with 2 µg of anti-LNA-1 or 10 µg of anti-v-FLIP antibodies. Immunoprecipitates were
extensively washed with lysis buffer and then resuspended in sample
buffer and loaded onto a 7% (for LNA-1) or 14% (for v-FLIP)
SDS-polyacrylamide gel. Dried gels were exposed to a phosphorimager
(Molecular Dynamics), and the relative levels of protein expression
were determined using densitometry software (Imagequant; Molecular
Dynamics). Apoptotic cells were quantitated by staining with
ANNEXIN-V-Fluos (Boehringer). Cells were washed twice with ice-cold PBS
and resuspended in 100 µl of annexin buffer (140 mM NaCl, 10 mM HEPES
[pH 7.4] 5 mM CaCl2) containing 2 µl of annexin. The
samples were incubated at room temperature in the dark for 15 min; at
the end of the incubation 300 µl of annexin buffer was added to all
samples, which were analyzed by FACScan.
 |
RESULTS |
An upstream RNA sequence allows v-FLIP translation in vitro.
In the viral bicistronic transcript, the v-cyclin coding sequence is
followed after 82 nt by the v-FLIP coding sequence. The constructs
shown in Fig. 1A were designed to examine
v-FLIP translation from this transcript in reticulocyte lysate.
v-cyclin and v-FLIP contain similar numbers of methionine and cysteine
residues for 35S incorporation (9 and 10, respectively). In
vitro transcription of these constructs produced a single bicistronic
RNA of approximately 1.5 kb, the predicted length, as shown in Fig. 1B.
Translation of the bicistronic v-cyclin/v-FLIP transcript gave a strong
v-cyclin band of 28 kDa and a slightly weaker 23-kDa v-FLIP band (Fig. 1C). v-FLIP expression was unlikely to be the result of cap-dependent translation, as the v-cyclin AUG lies within a strong Kozak consensus sequence (39) and a further five AUGs lie between the
v-cyclin start codon and the v-FLIP start codon. Translation of v-FLIP was then examined in bicistronic constructs containing mutations in the
v-cyclin coding region. In the first construct a guanosine residue in
the second codon for v-cyclin was deleted, resulting in a change of
frame to generate a predicted product of 10 amino acids, which was
undetectable. When codon 135 for v-cyclin was changed to a termination
codon, the predicted truncated protein of approximately 15 kDa was
detected. v-FLIP translation was unaffected by both mutations (Fig.
1C). This suggested that reinitiation of translation was not
responsible for v-FLIP expression because such reinitiation occurs
efficiently only after a short intercistronic gap (40).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
In vitro translation of the the v-cyclin/v-FLIP
cassette. The bicistronic plasmids (A), with monocistronic controls and
empty vector, were transcribed in vitro. RNA was analyzed on a 1%
agarose-formaldehyde gel (B) and translated in reticulocyte lysate as
described in Materials and Methods. (C) Labeled proteins resolved by
SDS-15% PAGE. HA, hemagglutinin.
|
|
To identify the region of the bicistronic transcript that allows v-FLIP
translation, three regions of the transcript were
cloned into a
bicistronic vector between the subunits of the heterodimeric
cytokine
IL-12, with the p40 initiation codon in the position
of that for v-FLIP
(Fig.
2A). Again in vitro transcription
produced
bicistronic RNAs of the expected lengths (Fig.
2B), which were
added to reticulocyte lysate to analyze translation. When the
intercistronic 82-nt region between the coding sequences for v-cyclin
and v-FLIP was inserted between the coding sequences for the two
IL-12
subunits a p35 signal but no p40 signal was seen, whereas
the 363- and
655-nt KSHV sequences allowed p40 translation. The
p40 band densities
seen with the two KSHV constructs were similar
to that seen with an
encephalomyocarditis virus (EMCV) IRES (Fig.
2C). p35 contains 18 potential methionine or cysteine residues
compared to 14 such residues
in p40, which may account for the
stronger intensity of the p35 signal.
The size of p35 is about
30 kDa, as p35 is extensively glycosylated in
vivo. Again cap-dependent
translation or reinitiation of translation
was unlikely to explain
p40 expression, as this was not observed with
the intercistronic
82-nt region. Therefore we concluded that an IRES
was present
upstream of the FLIP start codon and overlapping the
v-cyclin
coding sequence. It should be noted that translation of
v-cyclin
does not inhibit the activity of this IRES, as demonstrated in
Fig.
1C.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 2.
Mapping a region upstream of v-FLIP which allows
translation. The portions of the v-cyclin/v-FLIP cassette (A) and a
previously characterized IRES from EMCV (25) were cloned
between the coding sequences for the subunits of heterodimeric cytokine
IL-12. The bicistronic plasmids, with monocistronic controls and empty
vector, were transcribed in vitro. RNA was analyzed on a 1%
agarose-formaldehyde gel (B) and translated in reticulocyte lysate as
described in Materials and Methods. (C) Labeled proteins resolved by
SDS-12.5% PAGE.
|
|
Function of the IRES in mammalian cells.
The expression of
v-FLIP was also examined in mammalian cells where the cytomegalovirus
promoter drives expression of the bicistronic v-cyclin/v-FLIP
transcripts. Figure 3A shows that the
predicted 1.9-kb bicistronic transcript was detected in transfected 293T cells, with no shorter v-FLIP transcripts being detected even on
overexposure of the blot (data not shown). To detect v-FLIP expression,
we raised a polyclonal antiserum against a peptide corresponding to the
14 N-terminal amino acids. Figure 3B shows that both v-cyclin and
v-FLIP were expressed from the bicistronic message. p40 expression from
the bicistronic IL-12 cassettes was also examined following mammalian
cell transfection with expression vectors. Figure
4A shows that only the predicted
bicistronic transcripts encoding p40 were detected in the transfected
cells. Levels of p40, measured using an ELISA which detects p40 whether
present as a homodimer or heterodimer, are shown in Fig. 4B. A low
level of p40 was detected following the transfection of the vector
containing the 82-nt intercistronic v-cyclin/v-FLIP coding sequence
region. The vector containing the 655-nt v-cyclin/v-FLIP coding
sequence region produced more p40 than that the 363-nt region. The low activity of the 82-nt sequence is in contrast to its inactivity in
vitro. Furthermore, while a sequence of 363 nt can function optimally
in vitro, full activity in cells occurs with the longer 655-nt
sequence. This could imply that the interaction of cellular proteins
with sequences proximal to the 363-nt sequence is required for
translation or alternatively could suggest that the longer sequence is
required for optimum stability of an IRES structure in cells.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Function of the v-cyclin/v-FLIP transcript in mammalian
cells. 293T cells were transiently transfected with parental pcDNA
3.1(+) vector or with vectors containing the coding sequence for
bicistronic v-cyclin/v-FLIP. After 48 h, half the cells were used
to prepare RNA as described in Materials and Methods and half were
lysed in radioimmunoprecipitation assay buffer for SDS-PAGE. (A) RNA
probed with a v-FLIP probe. (B) v-cyclin and v-FLIP detected on a
Western blot as described in Materials and Methods.
|
|

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Mapping a region upstream of v-FLIP which allows
translation in mammalian cells. 293T cells were transiently transfected
with parental pcDNA 3.1(+) vector or with vectors containing sequences
from the v-cyclin/v-FLIP-coding region of KSHV between the coding
sequences for the subunits of the heterodimeric cytokine IL-12. The
same plasmid containing the IRES from EMCV was used for comparison.
After 48 h, cell supernatant was collected and the cells were used
to prepare RNA as described in Materials and Methods. (A) RNA probed
with a p40 probe. (B) Level of p40 protein in supernatant detected by
ELISA, as described in Materials and Methods. p40 levels are shown as
the means of triplicate determinations with standard errors of the
means (SEM).
|
|
v-FLIP expression in KSHV-transformed PEL cells.
To
demonstrate that v-FLIP is expressed from the bicistronic message
detected in latently infected cells, we used the polyclonal antiserum
which recognizes v-FLIP. Figure 5A shows
that this antiserum recognized a protein of approximately 23 kDa in
lysates from the EBV-negative PEL cell lines BC3 and BCP1, but not the
EBV-transformed cell line B.45. Induction of KSHV replication by
tetradecanoyl phorbol acetate in BC3 cells (25) caused
only a small increase in v-FLIP expression (Fig. 5A), demonstrating
that it is a latently expressed protein. Anti-v-FLIP rat monoclonal
antibody 6/14 was raised against full-length recombinant v-FLIP
expressed in E. coli. This monoclonal antibody also
recognized a protein of approximately 23 kDa in BC3 cell lysate (Fig.
5B) and stained the cytoplasm of BC3 cells (Fig.
6).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
v-FLIP protein expression in KSHV-infected B cells. (A)
Western blot of 70 µg of protein from the EBV-transformed B.45 cells
and the KSHV-transformed EBV-negative PEL BC3 and BCP1 cells and
protein from BC3 cells uninduced or induced for 48 h with 200 ng
of tetradecanoyl phorbol acetate (TPA)/ml and separated by SDS-14%
PAGE. Immunoblotting with a polyclonal anti-v-FLIP antiserum was
performed as described in Materials and Methods. (B) Western blot of 70 µg of protein from EBV-negative B-cell line DG75 and the
KSHV-transformed PEL BC3 cells separated by SDS-14% PAGE.
Immunoblotting with monclonal anti-v-FLIP antibody 6/14 was performed
as described in Materials and Methods.
|
|

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 6.
BC3 cells (×500 magnification) stained with a
second-layer antibody only (A) or monoclonal anti v-FLIP antibody 6/14,
where a brown stain in the cytoplasm was detected (B) as described in
Materials and Methods.
|
|
During apoptosis cap-dependent protein translation is inhibited due to
cleavage of eIF4G by caspase 3 (
11,
44). Recently,
the
translation of cellular proteins involved in apotosis induction,
myc
(
63) and apoptosis inhibition, XIAP (
32), was
shown to
be initiated from an IRES and therefore maintained during
apoptosis.
The rate of v-FLIP synthesis was therefore examined during
apoptosis
of PEL cell line BC3 induced by serum withdrawal, which
caused
eIF4G cleavage (data not shown) and induced apoptosis as
detected
by ANNEXIN-V-Fluos staining (Fig.
7B). For comparison the rate
of LNA-1
synthesis was measured, since this requires cap-dependent
protein
translation and since v-cyclin could not be immunoprecipitated
with the
available antibody. Figure
7A shows that the rate of
synthesis of LNA-1
decreased in serum-deprived cells whereas that
of v-FLIP was
maintained. Quantitation of the relative amounts
of newly synthesized
LNA-1 and v-FLIP demonstrated a threefold
increase in the ratio of
v-FLIP synthesis to LNA-1 synthesis during
apoptosis (Fig.
7). This is
a change similar to the previously
reported relative up-regulation of
myc (
63) or XIAP (
32) synthesis
during
apoptosis. Clearly v-FLIP synthesis may be relatively higher
in
individual apoptotic cells, as not all the cells are apoptotic
at any
one time (Fig.
7B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
Synthesis of LNA-1 and v-FLIP during apoptosis of PEL
cells. BC3 cells were serum starved for 20 h to induce apoptosis,
which was detected by ANNEXIN-V Fluos staining (B) as described in
Materials and Methods. Viable cells (107) were then pulsed
for 2 h with labeled methionine and cysteine, after which LNA-1
and v-FLIP were immunoprecipitated as described in Materials and
Methods and the immunoprecipitates were separated by SDS-7 or 14%
PAGE, respectively (A). The relative levels of labeled protein were
determined using densitometry software on a phosphorimager as described
in Materials and Methods. The FLIP/LNA-1 labeled-protein ratio was
normalized to 1 in cells with serum; the relative FLIP/LNA-1
labeled-protein ratio in cells without serum was 3.25. In a second
experiment cells were serum starved for 24 h and the relative
FLIP/LNA-1 labeled-protein ratio increased from 1 to 3.1 on serum
starvation.
|
|
 |
DISCUSSION |
We have demonstrated that a sequence upstream of the v-FLIP coding
sequence functions to allow translation by acting as an IRES. IRES have
previously been identified in RNA viruses with a positive-sense,
nonsegmented genome (4-7, 27, 28, 67); they possess
certain conserved RNA secondary structural features (35,
62). In such viruses the RNA must serve both as the genome and
as an mRNA for translation of viral proteins; thus IRES have been
thought to be crucial for this dual usage.
The putative IRES upstream of the v-FLIP coding sequence is the first
to be identified in a DNA virus; its presence and the unusual overlap
of the IRES with the v-cyclin coding sequence suggest that expression
of v-cyclin and v-FLIP needs to be tightly coordinated. Three other
gammaherpesviruses closely related to KSHV (1) are known
to contain adjacent v-cyclin and v-FLIP reading frames. In ateline
herpesvirus 3 (unpublished) (GenBank accession no. AF083424) and
herpesvirus saimiri (2) a single base pair separates the
v-cyclin and v-FLIP reading frames. Macaca mulatta
rhadinovirus 17577 shows spacing similar to that for KSHV, with 69 bp
between the v-cyclin and v-FLIP reading frames (57). Whether any of these viruses employ a bicistronic transcript to express
v-cyclin and v-FLIP remains to be determined. The nearest relative to
this group, the gammaherpesvirus murine herpesvirus 68, encodes
v-cyclin alone (1, 68), suggesting that v-FLIP was a later
acquisition from cellular DNA. A second bicistronic transcript from
KSHV may also use an IRES to allow expression of the G-protein-coupled
receptor (v-GPCR) during lytic replication (39).
We have also shown for the first time that v-FLIP is expressed in
latently infected PEL cell lines. These lines express Fas but are
resistant to Fas-mediated killing (data not shown). It is likely that
this v-FLIP inhibition of Fas-mediated cell killing is one mechanism by
which KSHV evades anti-viral cytotoxic T-lymphocyte (CTL) responses.
This may occur during persistent KSHV infection of immunocompetent
individuals, in whom KSHV-specific CTL have been detected
(48). However, v-FLIP expression continues when tumors
arise in immunosuppressed individuals, whose anti-KSHV CTL responses
are likely to be compromised. This suggests that v-FLIP also directly
affects the survival of the tumor cells.
The v-cyclin-CDK6 complex is resistant to inhibition by p16 and p21
(64), and its expression causes degradation of the p27 inhibitor (22, 43). It can therefore override normal
controls to induce G1/S-phase transition. However,
constitutive expression of molecules which potentiate G1/S
transition such as c-myc (23), E2F (51), and
cyclin D1 (58) in the absence of optimal growth factors or
v-cyclin in the presence of a high level of CDK6 (47) has
been shown to cause apoptosis. It therefore seems an attractive hypothesis that v-cyclin may cooperate with v-FLIP to transform endothelial cells and/or B cells, which could explain the need to link
their expression. Indeed, death receptor signaling is known to be
involved in apoptosis of myc-expressing cells following serum removal
(33) or of epithelial cells following substrate detachment
(55), and v-FLIP has been shown to activate NF-
B signaling (16). However, the fact that v-FLIP synthesis
can be up-regulated when apoptosis is triggered may also provide a survival advantage for KSHV-infected cells under some circumstances and
could be another reason for an IRES-dependent translation of v-FLIP.
 |
ACKNOWLEDGMENTS |
W. Low and M. Harries contributed equally to this work.
BC3 was kindly provided by Ethel Ceserman.
This work was supported by the Clinical Research and Development
Committee of the Special Trustees of the Middlesex Hospital and a
Cancer Research Campaign Fellowship for a Clinician awarded to M.H.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Windeyer
Institute of Medical Sciences, University College London, 46 Cleveland
St., London W1P 6DB, United Kingdom. Phone and Fax: 44-207-679-9301. E-mail: mary.collins{at}ucl.ac.uk.
 |
REFERENCES |
| 1.
| Alba, M. M., R. Das, C. Orengo, and P. Kellam. Genome wide function conservation and phylogeny in the
Herpesviridae. Genome Res., in press.
|
| 2.
|
Albrecht, J. C.,
J. Nicholas,
D. Biller,
K. R. Cameron,
B. Biesinger,
C. Newman,
S. Wittman,
M. A. Craxton,
H. Coleman,
B. Fleckenstein, and R. W. Honess.
1992.
Primary structure of the herpesvirus saimiri genome.
J. Virol.
66:5047-5058[Abstract/Free Full Text].
|
| 3.
|
Ballestas, M. E.,
P. A. Chatis, and K. M. Kaye.
1999.
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen.
Science
284:641-644[Abstract/Free Full Text].
|
| 4.
|
Belsham, G. J., and J. K. Brangwyn.
1990.
A region of the 5' noncoding region of foot-and-mouth disease virus RNA directs efficient internal initiation of protein synthesis within cells: involvement with the role of L protease in translational control.
J. Virol.
64:5389-5395[Abstract/Free Full Text].
|
| 5.
|
Berlioz, C., and J.-L. Darlix.
1995.
An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors.
J. Virol.
69:2214-2222[Abstract].
|
| 6.
|
Bienkowska-Szewczyk, K., and E. Ehrenfeld.
1988.
An internal 5'-noncoding region required for translation of poliovirus RNA in vitro.
J. Virol.
62:3068-3072[Abstract/Free Full Text].
|
| 7.
|
Borman, A., and R. J. Jackson.
1992.
Initiation of translation of human rhinovirus RNA: mapping the internal ribosome entry site.
Virology
188:685-696[CrossRef][Medline].
|
| 8.
|
Boshoff, C.
1998.
Coupling herpesvirus to angiogenesis: viral pirates on a cellular sea.
Nature
391:24-25[CrossRef][Medline].
|
| 9.
|
Boshoff, C.
1999.
Kaposi's sarcoma-associated herpesvirus, p. 157-190.
In
R. Newton, V. Beral, and R. A. Weiss (ed.), Cancer surveys: infections and human cancer. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 10.
|
Boshoff, C.,
S.-J. Gao,
L. E. Healy,
S. Matthews,
A. J. Thomas,
L. Coignet,
R. A. Warnke,
J. A. Strauchen,
E. Matutes,
O. W. Kamel,
P. S. Moore,
R. A. Weiss, and Y. Chang.
1998.
Establishment of a KSHV positive cell line (BCP-1) from peripheral blood and characterizing its growth in vivo.
Blood
91:1671-1679[Abstract/Free Full Text].
|
| 11.
|
Bushell, M.,
L. McKendrick,
R. U. Janicke,
M. J. Clemens, and S. J. Morley.
1999.
Caspase-3 is necessary and sufficient for cleavage of protein synthesis eukaryotic initiation factor 4G during apoptosis.
FEBS Lett.
451:332-336[CrossRef][Medline].
|
| 12.
|
Carbone, A.,
A. Gloghini,
D. Bontempo,
P. Monini,
U. Tirelli,
R. Volpe,
P. J. Browning, and G. Gaidano.
2000.
Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1).
Am. J. Pathol.
156:1209-1215[Abstract/Free Full Text].
|
| 13.
|
Cesarman, E.,
Y. Chang,
P. S. Moore,
J. W. Said, and D. M. Knowles.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N. Engl. J. Med.
332:1186-1191[Abstract/Free Full Text].
|
| 14.
|
Chang, Y.,
E. Cesarman,
M. S. Pessin,
F. Lee,
J. Culpepper,
D. M. Knowles, and P. S. Moore.
1994.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science
266:1865-1869[Abstract/Free Full Text].
|
| 15.
|
Chang, Y.,
P. S. Moore,
S. J. Talbot,
C. H. Boshoff,
T. Zarkowska,
K. Godden,
H. Paterson,
R. A. Weiss, and S. Mittnacht.
1996.
Cyclin encoded by KS herpesvirus.
Nature
382:410[CrossRef][Medline].
|
| 16.
|
Chaudhary, P. M.,
A. Jasmin,
M. Eby, and L. Hood.
1999.
Modulation of the NF-kappaB pathway by virally encoded death effector domain-containing proteins.
Oncogene
18:5738-5746[CrossRef][Medline].
|
| 17.
|
Davis, M. A.,
M. A. Sturzl,
C. Blasig,
A. Schreier,
H. G. Guo,
M. Reitz,
S. R. Opalenik, and P. J. Browning.
1997.
Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells.
J. Natl. Cancer Inst.
89:1829-1831[Free Full Text].
|
| 18.
|
Dittmer, D.,
M. Lagunoff,
R. Renne,
K. Stastus,
A. Haase, and D. Ganem.
1998.
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.
J. Virol.
72:8309-8315[Abstract/Free Full Text].
|
| 19.
|
Djerbi, M.,
V. Screpanti,
A. I. Catrina,
B. Bogen,
P. Biberfeld, and A. Grandien.
1999.
The inhibitor of death receptor signaling. FLICE-inhibitory protein, defines a new class of tumor progression factors.
J. Exp. Med.
190:1025-1031[Abstract/Free Full Text].
|
| 20.
|
Dupin, N.,
T. Diss,
P. Kellam,
M. Tulliez,
M.-Q. Du,
R. A. Weiss,
P. G. Isaacson, and C. Boshoff.
2000.
HHV-8 is associated with a plasmablastic variant of Castleman's disease that is linked to HHV-8 positive plasmablastic lymphoma.
Blood
95:1406-1412[Abstract/Free Full Text].
|
| 21.
|
Dupin, N.,
C. Fisher,
P. Kellam,
S. Ariad,
M. Tulliez,
N. Franck,
E. van Marck,
D. Salmon,
I. Gorin,
J.-P. Escande,
R. A. Weiss,
K. Alitalo, and C. Boshoff.
1999.
Distribution of HHV-8 positive cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
Proc. Natl. Acad. Sci. USA
96:4546-4551[Abstract/Free Full Text].
|
| 22.
|
Ellis, M.,
Y. P. Chew,
L. Fallis,
S. Freddersdorf,
C. Boshoff,
R. A. Weiss,
X. Lu, and S. Mittnacht.
1999.
Degradation of p27KIP cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
EMBO J.
18:644-653[CrossRef][Medline].
|
| 23.
|
Evan, G. I.,
A. H. Wyllie,
C. S. Gilbert,
T. D. Littlewood,
H. Land,
M. Brooks,
L. M. Waters, and D. C. Hancock.
1992.
Induction of apoptosis in fibroblasts by c-myc protein.
Cell
69:119-128[CrossRef][Medline].
|
| 24.
|
Flore, O., and S. J. Gao.
1997.
Effect of DNA synthesis inhibitors on Kaposi's sarcoma-associated herpesvirus cyclin and major capsid protein gene expression.
AIDS Res. Hum. Retroviruses
13:1229-1233[Medline].
|
| 25.
|
Friborg, J.,
W. Kong,
M. O. Hottiger, and G. J. Nabel.
1999.
p53 inhibition by the LANA protein of KSHV protects against cell death.
Nature
402:889-894[Medline].
|
| 26.
|
Gao, S. J.,
L. Kingsley,
M. Li,
W. Zheng,
C. Parravicini,
J. Ziegler,
R. Newton,
C. R. Rinaldo,
A. Saah,
J. Phair,
R. Detels,
Y. Chang, and P. S. Moore.
1996.
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.
Nat. Med.
2:925-928[CrossRef][Medline].
|
| 27.
|
Ghattas, I. R.,
J. R. Sanes, and J. E. Majors.
1991.
The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos.
Mol. Cell. Biol.
11:5848-5859[Abstract/Free Full Text].
|
| 28.
|
Glass, M. J.,
X. Y. Jia, and D. F. Summers.
1993.
Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5' noncoding region.
Virology
193:842-852[CrossRef][Medline].
|
| 29.
|
Godden-Kent, D.,
S. J. Talbot,
C. Boshoff,
Y. Chang,
P. Moore,
R. A. Weiss, and S. Mittnacht.
1997.
The cyclin encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1.
J. Virol.
71:4193-4198[Abstract].
|
| 30.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
CSHL Press, New York, N.Y.
|
| 31.
|
Harries, M.,
N. Phillipps,
R. Anderson,
G. Prentice, and M. Collins.
2000.
Comparison of bicistronic retroviral vectors containing IRES using expression of human IL-12 as a readout.
J. Gene Med.
2:243-249[CrossRef][Medline].
|
| 32.
|
Holcik, M.,
C. Lefebvre,
C. Yeh,
T. Chow, and R. G. Korneluk.
1999.
A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection.
Nat. Cell. Biol.
1:190-192[CrossRef][Medline].
|
| 33.
|
Hueber, A. O.,
M. Zornig,
D. Lyon,
T. Suda,
S. Nagata, and G. I. Evan.
1997.
Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.
Science
278:1305-1309[Abstract/Free Full Text].
|
| 33a.
|
IARC Working Group.
1997.
Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8.
IARC Monogr. Eval. Carcinog. Risks Hum.
70:1-492[Medline].
|
| 34.
|
Irmler, M.,
M. Thome,
M. Hahne,
P. Schneider,
K. Hofman,
V. Steiner,
J. L. Bodmer,
M. Schroter,
K. Burns,
C. Mattmann,
D. Rimoldi,
L. E. French, and J. Tschopp.
1997.
Inhibition of death receptor signals by cellular FLIP.
Nature
388:190-195[CrossRef][Medline].
|
| 35.
|
Jackson, R. J., and A. Kaminski.
1995.
Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond.
RNA
1:985-1000[Medline].
|
| 36.
|
Judde, J. G.,
V. Lacoste,
J. Briere,
E. Kassa-Kelembho,
E. Clyti,
P. Couppie,
C. Buchrieser,
M. Tulliez,
J. Morvan, and A. Gessain.
2000.
Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases.
J. Natl. Cancer Inst.
92:729-736[Abstract/Free Full Text].
|
| 37.
|
Kellam, P.,
C. Boshoff,
D. Whitby,
S. Matthews,
R. A. Weiss, and S. J. Talbot.
1997.
Identification of a major latent nuclear antigen (LNA-1) in the human herpesvirus 8 (HHV-8) genome.
J. Hum. Virol.
1:19-29[Medline].
|
| 38.
|
Kellam, P.,
D. Bourboulia,
N. Dupin,
S. Talbot,
C. Boshoff, and R. A. Weiss.
1999.
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8.
J. Virol.
73:5149-5155[Abstract/Free Full Text].
|
| 39.
|
Kirshner, J. R.,
K. Staskus,
A. Haase,
M. Lagunoff, and D. Ganem.
1999.
Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis.
J. Virol.
73:6006-6014[Abstract/Free Full Text].
|
| 40.
|
Kozak, M.
1987.
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.
Nucleic Acids Res.
15:8125-8148[Abstract/Free Full Text].
|
| 41.
|
Kozak, M.
1987.
Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes.
Mol. Cell. Biol.
7:3438-3445[Abstract/Free Full Text].
|
| 42.
|
Li, M.,
H. Lee,
D. W. Yoon,
J. C. Albrecht,
B. Fleckenstein,
F. Neipel, and J. U. Jung.
1997.
Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin.
J. Virol.
71:1984-1991[Abstract].
|
| 43.
|
Mann, D. J.,
E. S. Child,
C. Swanton,
H. Laman, and N. Jones.
1999.
Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.
EMBO J.
18:654-663[CrossRef][Medline].
|
| 44.
|
Marissen, W. E., and R. E. Lloyd.
1998.
Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells.
Mol. Cell. Biol.
18:7565-7574[Abstract/Free Full Text].
|
| 45.
|
Moore, P. S.,
C. Boshoff,
R. A. Weiss, and Y. Chang.
1996.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739-1744[Abstract/Free Full Text].
|
| 46.
|
Neipel, F.,
J.-C. Albrecht, and B. Fleckenstein.
1997.
Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?
J. Virol.
71:4187-4192[Medline].
|
| 47.
|
Ojala, P. M.,
M. Tiainen,
P. Salven,
T. Veikkola,
E. Castanos-Velez,
R. Sarid,
P. Biberfeld, and T. P. Makela.
1999.
Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.
Cancer Res.
59:4984-4989[Abstract/Free Full Text].
|
| 48.
|
Osman, M.,
T. Kubo,
Y. Gill,
F. Neipel,
J. Smith,
R. A. Weiss,
B. Gazzard,
C. Boshoff, and F. Gotch.
1999.
Identification of human herpesvirus-8-specific cytotoxic T-cell responses.
J. Virol.
73:6136-6140[Abstract/Free Full Text].
|
| 49.
|
Pelletier, J., and N. Sonenberg.
1988.
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA.
Nature
334:320-325[CrossRef][Medline].
|
| 50.
|
Platt, G. M.,
E. Cannell,
M. E. Cuomo,
S. Singh, and S. Mittnacht.
2000.
Detection of the human herpesvirus 8-encoded cyclin protein in primary effusion lymphoma-derived cell lines.
Virology
272:257-266[CrossRef][Medline].
|
| 51.
|
Qin, X. Q.,
D. M. Livingston,
W. G. Kaelin, Jr., and P. D. Adams.
1994.
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Proc. Natl. Acad. Sci. USA
91:10918-10922[Abstract/Free Full Text].
|
| 52.
|
Radkov, S. A.,
P. Kellam, and C. Boshoff.
2000.
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells.
Nat. Med.
6:1121-1127[CrossRef][Medline].
|
| 53.
|
Rainbow, L.,
G. M. Platt,
G. R. Simpson,
R. Sarid,
S. Gao,
H. Stoiber,
C. S. Herrington,
P. S. Moore, and T. F. Schulz.
1997.
The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen.
J. Virol.
71:5915-5921[Abstract].
|
| 54.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 55.
|
Rytomaa, M., and J. Downward.
1999.
Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis.
Curr. Biol.
9:1043-1046[CrossRef][Medline].
|
| 56.
|
Sarid, R.,
O. Flore,
R. A. Bohenzky,
Y. Chang, and P. S. Moore.
1998.
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).
J. Virol.
72:1005-1012[Abstract/Free Full Text].
|
| 57.
|
Searles, R. P.,
E. P. Bergquam,
M. K. Axthelm, and S. W. Wong.
1999.
Sequence and genomic analysis of a rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.
J. Virol.
73:3040-3053[Abstract/Free Full Text].
|
| 58.
|
Sofer-Levi, Y., and D. Resnitzky.
1996.
Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E.
Oncogene
13:2431-2437[Medline].
|
| 59.
|
Soulier, J.,
L. Grollet,
E. Oksenhendler,
P. Cacoub,
D. Cazals Hatem,
P. Babinet,
M. F. d'Agay,
J. P. Clauvel,
M. Raphael, and L. Degos.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Blood
86:1276-1280[Abstract/Free Full Text].
|
| 60.
|
Staskus, K. A.,
R. Sun,
G. Miller,
P. Racz,
A. Jaslowski,
C. Metroka,
H. Brett-Smith, and A. T. Haase.
1999.
Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
J. Virol.
73:4181-4187[Abstract/Free Full Text].
|
| 61.
|
Staskus, K. A.,
W. Zhong,
K. Gebhard,
B. Herndier,
H. Wang,
R. Renne,
J. Beneke,
J. Pudney,
D. J. Anderson,
D. Ganem, and A. T. Haase.
1997.
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.
J. Virol.
71:715-719[Abstract].
|
| 62.
|
Stewart, S. R., and B. L. Semler.
1997.
RNA determinants of picornavirus cap-independent translation initiation.
Semin. Virol.
8:242-255[CrossRef].
|
| 63.
|
Stoneley, M.,
S. A. Chappell,
C. L. Jopling,
M. Dickens,
M. MacFarlane, and A. E. Willis.
2000.
c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis.
Mol. Cell. Biol.
20:1162-1169[Abstract/Free Full Text].
|
| 64.
|
Swanton, C.,
D. J. Mann,
B. Fleckenstein,
F. Neipel,
G. Peters, and N. Jones.
1997.
Herpesviral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.
Nature
390:184-187[CrossRef][Medline].
|
| 65.
|
Talbot, S.,
R. A. Weiss,
P. Kellam, and C. Boshoff.
1999.
Transcriptional analysis of human herpesvirus-8 (HHV-8) open reading frames 71, 72, 73, K14 and 74 in a primary effusion lymphoma cell line.
Virology
257:84-94[CrossRef][Medline].
|
| 66.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Fickenscher,
E. Meini,
F. Neipel,
C. Mattmann,
K. Burns,
J. L. Bodmer,
M. Schroter,
C. Scaffidl,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[CrossRef][Medline].
|
| 67.
|
Tsukiyama-Kohara, K.,
N. Iizuka,
M. Kohara, and A. Nomoto.
1992.
Internal ribosome entry site within hepatitis C virus RNA.
J. Virol.
66:1476-1483[Abstract/Free Full Text].
|
| 68.
|
Virgin, H. W.,
P. Latreille,
P. Wamsley,
K. Hallsworth,
K. E. Weck,
A. J. Dal Canto, and S. H. Speck.
1997.
Complete sequence and genome analysis of murine gammaherpesvirus 68.
J. Virol.
71:5894-5904[Abstract].
|
Journal of Virology, March 2001, p. 2938-2945, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2938-2945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Deniz, N., Lenarcic, E. M., Landry, D. M., Thompson, S. R.
(2009). Translation initiation factors are not required for Dicistroviridae IRES function in vivo. RNA
15: 932-946
[Abstract]
[Full Text]
-
Rowe, H. M., Lopes, L., Brown, N., Efklidou, S., Smallie, T., Karrar, S., Kaye, P. M., Collins, M. K.
(2009). Expression of vFLIP in a Lentiviral Vaccine Vector Activates NF-{kappa}B, Matures Dendritic Cells, and Increases CD8+ T-Cell Responses. J. Virol.
83: 1555-1562
[Abstract]
[Full Text]
-
Efklidou, S., Bailey, R., Field, N., Noursadeghi, M., Collins, M. K.
(2008). vFLIP from KSHV inhibits anoikis of primary endothelial cells. J. Cell Sci.
121: 450-457
[Abstract]
[Full Text]
-
Du, M-Q, Bacon, C M, Isaacson, P G
(2007). Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J. Clin. Pathol.
60: 1350-1357
[Abstract]
[Full Text]
-
Baird, S. D., Turcotte, M., Korneluk, R. G., Holcik, M.
(2006). Searching for IRES. RNA
12: 1755-1785
[Abstract]
[Full Text]
-
Haque, M., Wang, V., Davis, D. A., Zheng, Z.-M., Yarchoan, R.
(2006). Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster. J. Virol.
80: 7037-7051
[Abstract]
[Full Text]
-
Allen, R. D. III, Dickerson, S., Speck, S. H.
(2006). Identification of Spliced Gammaherpesvirus 68 LANA and v-Cyclin Transcripts and Analysis of Their Expression In Vivo during Latent Infection. J. Virol.
80: 2055-2062
[Abstract]
[Full Text]
-
Pearce, M., Matsumura, S., Wilson, A. C.
(2005). Transcripts Encoding K12, v-FLIP, v-Cyclin, and the MicroRNA Cluster of Kaposi's Sarcoma-Associated Herpesvirus Originate from a Common Promoter. J. Virol.
79: 14457-14464
[Abstract]
[Full Text]
-
Zhang, X., Wang, J. F., Chandran, B., Persaud, K., Pytowski, B., Fingeroth, J., Groopman, J. E.
(2005). Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection. J. Biol. Chem.
280: 26216-26224
[Abstract]
[Full Text]
-
Griffiths, A., Coen, D. M.
(2005). An unusual internal ribosome entry site in the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA
102: 9667-9672
[Abstract]
[Full Text]
-
Matsumura, S., Fujita, Y., Gomez, E., Tanese, N., Wilson, A. C.
(2005). Activation of the Kaposi's Sarcoma-Associated Herpesvirus Major Latency Locus by the Lytic Switch Protein RTA (ORF50). J. Virol.
79: 8493-8505
[Abstract]
[Full Text]
-
Klass, C. M., Krug, L. T., Pozharskaya, V. P., Offermann, M. K.
(2005). The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood
105: 4028-4034
[Abstract]
[Full Text]
-
Coleman, H. M., Efstathiou, S., Stevenson, P. G.
(2005). Transcription of the murine gammaherpesvirus 68 ORF73 from promoters in the viral terminal repeats. J. Gen. Virol.
86: 561-574
[Abstract]
[Full Text]
-
Jang, G. M., Leong, L. E.-C., Hoang, L. T., Wang, P. H., Gutman, G. A., Semler, B. L.
(2004). Structurally Distinct Elements Mediate Internal Ribosome Entry within the 5'-Noncoding Region of a Voltage-gated Potassium Channel mRNA. J. Biol. Chem.
279: 47419-47430
[Abstract]
[Full Text]
-
Ye, F.-C., Zhou, F.-C., Yoo, S. M., Xie, J.-P., Browning, P. J., Gao, S.-J.
(2004). Disruption of Kaposi's Sarcoma-Associated Herpesvirus Latent Nuclear Antigen Leads to Abortive Episome Persistence. J. Virol.
78: 11121-11129
[Abstract]
[Full Text]
-
Sakakibara, S., Ueda, K., Nishimura, K., Do, E., Ohsaki, E., Okuno, T., Yamanishi, K.
(2004). Accumulation of Heterochromatin Components on the Terminal Repeat Sequence of Kaposi's Sarcoma-Associated Herpesvirus Mediated by the Latency-Associated Nuclear Antigen. J. Virol.
78: 7299-7310
[Abstract]
[Full Text]
-
Conticello, C., Pedini, F., Zeuner, A., Patti, M., Zerilli, M., Stassi, G., Messina, A., Peschle, C., De Maria, R.
(2004). IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins. J. Immunol.
172: 5467-5477
[Abstract]
[Full Text]
-
Guasparri, I., Keller, S. A., Cesarman, E.
(2004). KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells. JEM
199: 993-1003
[Abstract]
[Full Text]
-
Bieleski, L., Hindley, C., Talbot, S. J.
(2004). A polypyrimidine tract facilitates the expression of Kaposi's sarcoma-associated herpesvirus vFLIP through an internal ribosome entry site. J. Gen. Virol.
85: 615-620
[Abstract]
[Full Text]
-
Kaiser, W. J., Kaufman, J. L., Offermann, M. K.
(2004). IFN-{alpha} Sensitizes Human Umbilical Vein Endothelial Cells to Apoptosis Induced by Double-Stranded RNA. J. Immunol.
172: 1699-1710
[Abstract]
[Full Text]
-
An, J., Sun, Y., Rettig, M. B.
(2004). Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood
103: 222-228
[Abstract]
[Full Text]
-
Coleman, H. M., Brierley, I., Stevenson, P. G.
(2003). An Internal Ribosome Entry Site Directs Translation of the Murine Gammaherpesvirus 68 MK3 Open Reading Frame. J. Virol.
77: 13093-13105
[Abstract]
[Full Text]
-
Hood, C., Cunningham, A. L., Slobedman, B., Boadle, R. A., Abendroth, A.
(2003). Varicella-Zoster Virus-Infected Human Sensory Neurons Are Resistant to Apoptosis, yet Human Foreskin Fibroblasts Are Susceptible: Evidence for a Cell-Type-Specific Apoptotic Response. J. Virol.
77: 12852-12864
[Abstract]
[Full Text]
-
Field, N., Low, W., Daniels, M., Howell, S., Daviet, L., Boshoff, C., Collins, M.
(2003). KSHV vFLIP binds to IKK-{gamma} to activate IKK. J. Cell Sci.
116: 3721-3728
[Abstract]
[Full Text]
-
Fujimuro, M., Hayward, S. D.
(2003). The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Manipulates the Activity of Glycogen Synthase Kinase-3{beta}. J. Virol.
77: 8019-8030
[Abstract]
[Full Text]
-
Beales, L. P., Holzenburg, A., Rowlands, D. J.
(2003). Viral Internal Ribosome Entry Site Structures Segregate into Two Distinct Morphologies. J. Virol.
77: 6574-6579
[Abstract]
[Full Text]
-
Hay, S., Kannourakis, G.
(2002). A time to kill: viral manipulation of the cell death program. J. Gen. Virol.
83: 1547-1564
[Abstract]
[Full Text]
-
Tang, S., Zheng, Z.-M.
(2002). Kaposi's Sarcoma-associated Herpesvirus K8 Exon 3 Contains Three 5'-Splice Sites and Harbors a K8.1 Transcription Start Site. J. Biol. Chem.
277: 14547-14556
[Abstract]
[Full Text]
-
Sharp, T. V., Wang, H.-W., Koumi, A., Hollyman, D., Endo, Y., Ye, H., Du, M.-Q., Boshoff, C.
(2002). K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus Is Latently Expressed and Binds to HAX-1, a Protein with Antiapoptotic Function. J. Virol.
76: 802-816
[Abstract]
[Full Text]
-
Krueger, A., Baumann, S., Krammer, P. H., Kirchhoff, S.
(2001). FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis. Mol. Cell. Biol.
21: 8247-8254
[Full Text]